Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan.
Koichi TakaguchiHidenori ToyodaAkemi TsutsuiYoshiyuki SuzukiMakoto NakamutaMichio ImamuraTomonori SenohTakuya NaganoToshifumi TadaYoshihiko TachiAtsushi HiraokaKojiro MichitakaHiroshi ShibataKouji JokoHironao OkuboKunihiko TsujiShintaro TakakiTsunamasa WatanabeChikara OgawaKazuaki ChayamaTakashi KumadaMasatoshi KudoHiromitsu KumadaPublished in: Journal of gastroenterology (2019)
Many patients treated with the DCV/ASV/BCV regimen have a history of a failure to achieve SVR with previous IFN-free DAA therapy. SVR rate was not as high as that in pre-approval clinical trial of this regimen in IFN-free DAA-naïve patients. In addition, most patients with a history of failure with IFN-free DAA therapy, particularly the DCV/ASV regimen, showed resistance to this regimen.
Keyphrases
- hepatitis c virus
- human immunodeficiency virus
- clinical trial
- immune response
- dendritic cells
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- stem cells
- study protocol
- cell therapy
- patient reported outcomes
- phase ii
- combination therapy
- hiv infected patients
- smoking cessation
- replacement therapy